Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 4/20 | 0.77 |
| ▸ | DYRK1B | Q9Y463 | 3/20 | 0.69 |
| ▸ | DYRK2 | Q92630 | 1/20 | 0.69 |
| ▸ | CYP2A6 | P11509 | 13/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.59 |
| ▸ | CYP2B6 | P20813 | 6/20 | 0.59 |
| ▸ | CYP2E1 | P05181 | 5/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12601804 | 0.84 | DYRK1A (0.60) | DYRK1ADYRK1BDYRK2CYP2A6CYP3A4 | |
| SCHEMBL24089574 | 0.82 | DYRK1A (0.56) | DYRK1ADYRK1BDYRK2CYP2A6CYP3A4 | |
| SCHEMBL48894 | 0.82 | DYRK1A (0.55) | DYRK1ADYRK1BDYRK2ALDH1A1KDM4E | |
| Ammonia Solution, Strong SCHEMBL28177501 | 0.80 | DYRK1A (0.53) | DYRK1ADYRK1BDYRK2ALDH1A1KDM4E | |
| SCHEMBL8686043 | 0.79 | — | — | |
| SCHEMBL1771536 | 0.79 | DYRK1A (0.58) | DYRK1ADYRK1BDYRK2CYP2A6CYP3A4 | |
| SCHEMBL1872880 | 0.77 | DYRK1A (0.55) | DYRK1ADYRK1BDYRK2CYP2A6CYP3A4 | |
| SCHEMBL29360677 | 0.76 | CYP2A6 (0.88) | DYRK1ADYRK1BCYP2A6CYP3A4CYP2C9 | |
| SCHEMBL13907273 | 0.76 | CYP2A6 (0.88) | DYRK1ADYRK1BCYP2A6CYP3A4CYP2C9 | |
| SCHEMBL24534338 | 0.76 | CYP2A6 (0.88) | DYRK1ADYRK1BCYP2A6CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230052191-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2023-02-16 | — | — | US | disclosed |
| US-20200369658-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2020-11-26 | — | — | US | disclosed |
| US-9926307-B2 | Compounds | MISSION THERAPEUTICS LTD (GB) | 2018-03-27 | — | — | US | disclosed |
| US-20170334948-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | NOVALIX DEUTSCHLAND GMBH (DE) | 2017-11-23 | — | — | US | disclosed |
| US-20170247365-A1 | NOVEL COMPOUNDS | MISSION THERAPEUTICS LTD (GB) | 2017-08-31 | — | — | US | disclosed |
| US-9745339-B2 | Ligands for antibody and Fc-fusion protein purification by affinity chromotography IV | NOVALIX DEUTSCHLAND GMBH (DE) | 2017-08-29 | — | — | US | disclosed |
| US-20160009760-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | GRAFFINITY PHARMACEUTICALS GMBH (DE) | 2016-01-14 | — | — | US | disclosed |
| US-20150373978-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS PESTICIDES | BAYER IP GMBH (DE) | 2015-12-31 | — | — | US | disclosed |
| US-9173396-B2 | Heterocyclic compounds as pesticides | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-11-03 | — | — | US | disclosed |
| CN-104395335-A | Ligands for antibody and fc-fusion protein purification by affinity chromotography iv | GRAFFINITY PHARMACEUTICALS GMBH | 2015-03-04 | — | — | CN | disclosed |
| US-20100168005-A1 | Pyridin-3-yl derivatives as immunomodulating agents | ACTELION PHARMACEUTICALS LTD. (CH) | 2010-07-01 | — | — | US | disclosed |
| CN-101522670-A | Pyridin-3-yl derivatives as immunomodulators | ACTELION PHARMACEUTICALS LTD (CH) | 2009-09-02 | — | — | CN | disclosed |
| EP-2069335-A1 | PYRIDIN-3-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | Actelion Pharmaceuticals Ltd. (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2008029370-A1 | PYRIDIN-3-YL DERIVATIVES AS IMMUNOMODULATING AGENTS | ACTELION PHARMACEUTICALS LTD (CH) | 2008-03-13 | — | — | WO | disclosed |
| EP-1893607-A2 | INHIBITORS OF CHECKPOINT KINASES | Merck & Co., Inc. (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006135604-A2 | INHIBITORS OF CHECKPOINT KINASES | MERCK & CO., INC. (US) | 2006-12-21 | — | — | WO | disclosed |
| US-6747023-B1 | INHIBITORS FOR ACTIVATED COAGULATION FACTOR X, COAGULATION SUPPRESSORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1104754-A1 | NOVEL SULFONYL DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2001-06-06 | — | — | EP | disclosed |
| US-5106732-A | Using oxazole or thiazole derivative | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082611-A1 | Anticoagulants; brain disorders; respiratory system disorders; side effect reduction | F2, CYC1, SULT2A1 | DYRK1A 1092/4885DYRK1B 1711/4885DYRK2 1777/4885 |
| US-20170334948-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | FCGR1A, FCGR2A, FCGR3B | DYRK1A 4517/4885DYRK1B 4589/4885DYRK2 4377/4885 |
| US-20160009760-A1 | LIGANDS FOR ANTIBODY AND FC-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMOTOGRAPHY IV | FCGR1A, FCGR2A, FCGR3B | DYRK1A 4475/4885DYRK1B 4540/4885DYRK2 4296/4885 |
| US-20200369658-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | DYRK1A 1587/4885DYRK1B 1695/4885DYRK2 2505/4885 |
| US-20170247365-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | DYRK1A 1587/4885DYRK1B 1695/4885DYRK2 2505/4885 |
| US-20100168005-A1 | Pyridin-3-yl derivatives as immunomodulating agents | CD4, FCGRT, CD47 | DYRK1A 1085/4885DYRK1B 1364/4885DYRK2 1123/4885 |
| US-20150373978-A1 | NOVEL HETEROCYCLIC COMPOUNDS AS PESTICIDES | DDT, ACHE, PTMS | DYRK1A 4297/4885DYRK1B 4375/4885DYRK2 4238/4885 |
| US-20230052191-A1 | NOVEL COMPOUNDS | UCHL1, UCHL3, UCHL5 | DYRK1A 1587/4885DYRK1B 1695/4885DYRK2 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.